Other News Releases in Biotechnology
ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries
Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category
American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
Other News Releases in Personnel Announcements
New Tri Tax President and CEO Frank Montano Brings Years of Corporate Leadership to Booming Company
Kelaher Joins Duck Creek's Board of Directors
Richmond Fed Announces Officer Promotions
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
See more news releases in: Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements
Sequoia Pharmaceuticals Announces Appointment of Steven D. Skolsky as Chief Executive Officer
GAITHERSBURG, Md., Oct. 29 /PRNewswire/ -- Sequoia Pharmaceuticals,
Inc., which discovers and develops novel antiviral therapeutics as well as
pharmacokinetic enhancers, announced today the appointment of Steven D.
Skolsky as its President and Chief Executive Officer. He will also serve as
a member of the Board of Directors.
"Sequoia is pleased to have recruited such an outstanding, talented
leader as Steven Skolsky," said Chris Mirabelli, Chairman of the Board of
Sequoia Pharmaceuticals. "Steve has an impressive record of success within
the pharmaceutical industry. The combination of his leadership and
management experience, as well as his business acumen, makes Steve uniquely
qualified to lead us through the exciting times ahead."
"Sequoia possesses an extraordinary scientific pedigree, and a very
attractive research portfolio. I am honored to have the opportunity to lead
Sequoia, and to build on its outstanding technological progress as we move
towards commercialization", said Mr. Skolsky.
Mr. Skolsky brings over twenty-five years of U.S. and international
experience in the pharmaceutical and biotechnology arena. He most recently
served as chief executive officer of Trimeris, a biotechnology company
specializing in HIV therapeutics. Previously Mr. Skolsky had a
distinguished career at GlaxoSmithKline where he served as GSK's Senior
Vice President of Global Commercial Strategy responsible for world-wide
clinical development and product strategy. He also served as managing
director of GSK's operations in Australia and New Zealand and previously
was Vice President of Sales and Marketing of the HIV/Oncology Division at
Glaxo Wellcome. He is a graduate of the University of North Carolina at
Chapel Hill.
About Sequoia Pharmaceuticals, Inc.
Sequoia Pharmaceuticals discovers and develops revolutionary new
treatments, primarily for viral diseases including HIV/AIDS and HCV-induced
hepatitis. In addition, Sequoia has an active R&D program in
pharmacokinetic enhancers.
SOURCE Sequoia Pharmaceuticals, Inc.













